Using a data platform29 to analyze more than 15 years of longitudinal EHRs of a US population-based cohort of more than 100 million individuals, we found that in patients with T2D who had no history of any OAC, GLP-1RAs compared with insulins were associated with a significant risk reduction in 10 of 13 OACs, including esophageal, colorectal, kidney, pancreatic, gallbladder, ovarian, endometrial, and liver cancers as well as meningioma and multiple myeloma. Here, INS is linked to plasma cell myeloma.